PMID- 19929593
OWN - NLM
STAT- MEDLINE
DCOM- 20100430
LR  - 20181201
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 26
IP  - 2
DP  - 2010 Feb
TI  - A 25-week, open-label trial investigating rivastigmine transdermal patches with 
      concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc 
      analysis.
PG  - 263-9
LID - 10.1185/03007990903434914 [doi]
AB  - OBJECTIVE: To investigate the tolerability and efficacy of the rivastigmine 
      transdermal patch in patients with mild-to-moderate Alzheimer's disease receiving 
      concomitant memantine. RESEARCH DESIGN AND METHODS: Post hoc analysis of a 
      25-week, randomized, prospective, open-label, parallel-group study. Patients 
      receiving donepezil were switched to rivastigmine patches (4.6 mg/24 h) 
      immediately or following a 7-day withdrawal for 4 weeks (core phase), before 
      titrating up to 9.5 mg/24 h for a further 20-week extension phase. Prior 
      memantine therapy was continued throughout. MAIN OUTCOME MEASURES: Tolerability 
      (adverse events [AEs], serious AEs [SAEs] and discontinuations) and efficacy 
      (cognition, global functioning and activities of daily living [ADLs]) were 
      assessed for the rivastigmine transdermal patch, with or without concomitant 
      memantine. RESULTS: Overall, 135 and 126 patients received rivastigmine with and 
      without memantine, respectively. Of these, 122 (90.4%) and 118 (93.7%) patients 
      with and without memantine, respectively, completed the core phase; 120 and 114 
      patients, respectively, entered the extension phase, and 90 (75.0%) and 86 
      (75.4%) completed the study. The incidences of AEs (73.3 vs. 67.5%) and SAEs 
      (10.4 vs. 7.1%) were both slightly larger in patients receiving concomitant 
      memantine, but the differences were not statistically significant (95% CIs: -5.2, 
      16.9 and -3.6, 10.1 for AEs and SEAs, respectively). The incidence of 
      gastrointestinal AEs was low in both groups. Discontinuation due to AEs was 
      higher in patients who received memantine (17.0 vs. 11.9%). Changes in cognitive 
      and global function were similar between groups. ADL scores worsened in both 
      groups; significantly more in those treated with memantine. CONCLUSION: Use of 
      the rivastigmine transdermal patch in patients on established memantine appears 
      to be well-tolerated, with only modest, non-significant increases in AEs compared 
      with monotherapy, and did not seem to affect cognition or global functioning 
      adversely.
FAU - Farlow, Martin R
AU  - Farlow MR
AD  - Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 
      46202, USA. mfarlow@iupui.edu
FAU - Alva, Gus
AU  - Alva G
FAU - Meng, Xiangyi
AU  - Meng X
FAU - Olin, Jason T
AU  - Olin JT
LA  - eng
SI  - ClinicalTrials.gov/NCT00428389
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Antiparkinson Agents)
RN  - 0 (Cholinesterase Inhibitors)
RN  - 0 (Indans)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Phenylcarbamates)
RN  - 0 (Piperidines)
RN  - 8SSC91326P (Donepezil)
RN  - PKI06M3IW0 (Rivastigmine)
RN  - W8O17SJF3T (Memantine)
SB  - IM
MH  - Administration, Cutaneous
MH  - Aged
MH  - Aged, 80 and over
MH  - Algorithms
MH  - Alzheimer Disease/*drug therapy/pathology
MH  - Antiparkinson Agents/administration & dosage/adverse effects
MH  - Cholinesterase Inhibitors/administration & dosage/adverse effects
MH  - Donepezil
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Indans/administration & dosage
MH  - Male
MH  - Memantine/*administration & dosage/adverse effects
MH  - Middle Aged
MH  - Neuroprotective Agents/administration & dosage/adverse effects
MH  - Phenylcarbamates/*administration & dosage/adverse effects
MH  - Piperidines/administration & dosage
MH  - Rivastigmine
MH  - Severity of Illness Index
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2009/11/26 06:00
MHDA- 2010/05/01 06:00
CRDT- 2009/11/26 06:00
PHST- 2009/11/26 06:00 [entrez]
PHST- 2009/11/26 06:00 [pubmed]
PHST- 2010/05/01 06:00 [medline]
AID - 10.1185/03007990903434914 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2010 Feb;26(2):263-9. doi: 10.1185/03007990903434914.